[SAN] FW: Study raises possible cancer concerns for Ritalin

  • From: "Frick, Ann" <a.frick@xxxxxxxxxxxxxx>
  • To: <san-list@xxxxxxxxxxxxx>
  • Date: Thu, 3 Mar 2005 13:54:29 -0000

Here is a link to the study Wolfgang mentioned.  
annie
-----Original Message-----
From: Thom Hartmann [mailto:Nigel@xxxxxxxxxxxxxxx]
Sent: 27 February 2005 02:51
To: Frick, Ann
Subject: Study raises possible cancer concerns for Ritalin 

This research was just published and I felt it worth sharing with you. There's 
a discussion of it on our message board at www.thomhartmann.com. 
Best regards,
Thom 

ScienceDirect's Cancer Letters (PDF copies can be obtained by contacting the 
UTMB public affairs office at  
<http://www.sciencedirect.com/science/journal/03043835> 
http://www.sciencedirect.com/science/journal/03043835). 

Study Shows Methylphenidate Linked to Chromosomal Changes 


Source: University of  <http://www.newswise.com/institutions/view/?id=318> 
Texas Medical Branch at Galveston 

Released: Thu 24-Feb-2005, 14:00 ET 

http://www.newswise.com/articles/view/510069/ 

Description 

A new study found that every one of a dozen children treated for attention 
deficit/ hyperactivity disorder with methylphenidate experienced a threefold 
increase in levels of chromosome abnormalities-occurrences associated with 
increased risks of cancer and other adverse health effects. 

Newswise - In a small but startling preliminary new study, Texas researchers 
have found that after just three months, every one of a dozen children treated 
for attention deficit/hyperactivity disorder (ADHD) with the drug 
methylphenidate experienced a threefold increase in levels of chromosome 
abnormalities-occurrences associated with increased risks of cancer and other 
adverse health effects. 

The researchers say that to their knowledge this is the first study addressing 
the potential chromosome-breaking effects associated with treatment of children 
with methylphenidate, the generic name for a group of drugs that includes 
Ritalin, Concerta, Metadate CD and others. 

Methylphenidate is the most widely prescribed of a class of amphetamine-like 
drugs used to treat ADHD, with more than 10 million prescriptions written for 
it in 1996 alone. Between 1991 and 1999, United States sales of methylphenidate 
increased more than 500 percent. 

Researchers at The University of Texas M.D. Anderson Cancer Center in Houston 
and the University of Texas Medical Branch at Galveston (UTMB) reported their 
detection of the chromosome abnormalities in the journal Cancer Letters. Their 
peer-reviewed paper is to be published several months hence, but the journal 
editors have made it available online in the journal's "articles in press" 
section. 

The authors said they undertook the study because, even though methylphenidate 
has been approved for human use for more than 50 years, "there are surprisingly 
few studies" in either animals or human beings "on the potential for serious 
side effects," such as causing mutations and cancer. In 1996, a report 
discussing several two-year-long animal studies showed that the highest levels 
of methylphenidate tested caused liver tumors in male and female mice. However, 
similar studies in rats showed no such tumors. 

The new Texas study involved researchers drawing blood from children diagnosed 
with ADHD before they began taking methylphenidate in order to get a baseline 
level of chromosomal abnormalities. Three months after the children had begun 
taking the drug, the researchers drew the children's blood and tested it a 
second time. Chromosomes are the bodies within cells that carry the genes and 
genetic information. All 12 of the children whose before-and-after blood cells 
were studied were treated with normal therapeutic doses of methylphenidate. 

Most of the abnormalities found in the studied blood cells consisted of 
chromosome breaks "and a higher frequency of aberrations is reported to be 
associated with an increased risk of cancer down the line," said lead author 
Randa A. El-Zein, M.D., Ph.D., an assistant professor of epidemiology at M.D. 
Anderson who performed the blood studies using several techniques.

"It was pretty surprising that all of the children taking methylphenidate 
showed an increase in chromosome abnormalities in a relatively short period of 
time," El-Zein said. 

UTMB Professor of Environmental Toxicology Marvin Legator, the study's 
principal investigator and senior author, cautioned, "This study doesn't mean 
that these kids are going to get cancer, but it does mean they are exposed to 
an additional risk factor, assuming that this study holds up." Of the 53 known 
human carcinogens, Legator said 48 could be detected using the chromosome 
analysis methods employed in this study. 

El-Zein stressed that much larger studies at several medical centers are needed 
to confirm the results of this study and to answer other questions not 
addressed by it. One of these issues is the question of what happens when 
patients stop taking methylphenidate. "Do the levels of chromosome 
abnormalities go back to normal?" El-Zein said. "We don't know." 

Parents should respond cautiously to this preliminary study, El-Zein said, 
noting that there are few alternatives to methylphenidate for treating ADHD. 

Asked what he would do in response to the study if his child were on 
methylphenidate, co-author Matthew J. Hay, a UTMB pediatrician who treated all 
the children who participated in the study, was equally guarded. "Twelve kids 
with one physician in one county is too small a sample to base a decision on," 
he said. "If my child were on the medication and were doing well, I wouldn't 
take him off it" unless additional studies showed similar effects.

The Cancer Letters article by Randa A. El-Zein, Sherif Z. Abdel-Rahman, Matthew 
J. Hay, Mirtha S. Lopez, Melissa L. Bondy, Debra L. Morris and Marvin S. 
Legator can be found on the Web by clicking the "Articles in Press" button on 
ScienceDirect's Cancer Letters page (  
<http://www.sciencedirect.com/science/journal/03043835> 
http://www.sciencedirect.com/science/journal/03043835). PDF copies can be 
obtained by contacting the UTMB public affairs office at the email addresses or 
phone numbers above. 





Other related posts: